Unexpected neurotoxicity in dogs receiving a cyclophosphamide, dactinomycin, and 5-fluorouracil chemotherapy protocol.
An inexpensive combination chemotherapy protocol containing cyclophosphamide, dactinomycin, and 5-fluorouracil was evaluated in dogs with carcinomas. Fifteen dogs were entered in this study, and there were 1 complete response and 2 partial responses among 12 evaluable dogs. However, 6 of 15 dogs (40%) developed neurotoxicity. The neurotoxicity of this protocol was compared with a previous 5-fluorouracil-containing protocol and found to be significantly higher. Due to the unacceptably high rate of neurotoxicity, this protocol cannot be recommended for use in dogs with cancer.
Hammer
A S
AS
Department of Veterinary Clinical Sciences, Ohio State University, Columbus 43210.
Carothers
M A
MA
Harris
C L
CL
O'Keefe
D A
DA
Ayl
R D
RD
Peterson
J L
JL
Shank
K A
KA
Couto
C G
CG
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000662:veterinary*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D008297:Male; D009422:Nervous System Diseases / Q000139:chemically induced*; D016896:Treatment Outcome
D003609:Dactinomycin; D003520:Cyclophosphamide; D005472:Fluorouracil